Rocio Martin Hoyos, Chief Strategy Officer of Atrium Therapeutics, Inc., filed a statement of changes in beneficial ownership on September 22, 2026, disclosing a transaction in common stock dated September 18, 2026.

Key Highlights

  • Reporting person: Rocio Martin Hoyos, identified as Chief Strategy Officer of Atrium Therapeutics, Inc.
  • Transaction type: 8,320 shares of common stock were disposed of (code F) at $8.95 per share on September 18, 2026.
  • Purpose of disposition: According to the filing, the shares were withheld by the issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units.
  • Remaining ownership: Following the transaction, Hoyos directly held 38,340 shares of common stock, per the filing.
  • Filing date: The statement was signed by Brendan Winslow as Attorney-in-Fact and filed on September 22, 2026.

Chief Strategy Officer Share Withholding at Atrium Therapeutics

According to the filing, Rocio Martin Hoyos, who serves as Chief Strategy Officer of Atrium Therapeutics, Inc. (NASDAQ:RNA), reported a single transaction in Table I covering non-derivative securities. On September 18, 2026, a total of 8,320 shares of common stock were disposed of at a price of $8.95 per share under transaction code F, which the filing's footnote specifies represents shares withheld by the issuer to satisfy tax withholding obligations arising from the vesting of restricted stock units.

Atrium Therapeutics, Inc. is identified in the filing as the issuer, with its address listed at 10578 Science Center Drive, Suite 125, San Diego, California 92121. No derivative securities transactions were reported in Table II of the filing. The filing was made by one reporting person and was not indicated as an amendment to a prior filing. Following the reported disposition, Hoyos directly held 38,340 shares of Atrium Therapeutics common stock, as disclosed in the filing.

The statement was executed by Brendan Winslow in the capacity of Attorney-in-Fact on September 22, 2026. No Rule 10b5-1 trading plan box was checked, and the filing does not indicate that Hoyos is no longer subject to Section 16 reporting obligations. No additional transactions or derivative security holdings were reported.

What Was Disclosed

The filing disclosed that Atrium Therapeutics Chief Strategy Officer Rocio Martin Hoyos had 8,320 shares withheld at $8.95 per share on September 18, 2026, for tax withholding on vesting restricted stock units, leaving her with a direct holding of 38,340 shares.